Phase II/III data showed that advanced gastric cancer patients on anbenitamab and chemotherapy fared better than those on standard therapy.

Cambridge, Massachusetts-based Amylyx announced pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10 per share. The firm has also ...

Sheba will extend the use of Imagene's cross-modality intelligence engine and suite of tools, initially deployed in lung cancer, across cancer indications.

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

The firm has voluntarily halted the SYNRGY study so it can investigate what caused the patient's death and will assess next steps based on the findings.

Some feel the guidance may encourage consistent follow-up of overall survival after accelerated approvals, but others remain focused on speeding new drugs to patients.

Autonomous AI tools have great potential in supporting precision medicine, but developers are still figuring out how to deploy them in patient care.

The company announced results from a Phase Ib trial of the drug as a first-line monotherapy for EGFR PACC-mutated NSCLC.

The AI-enabled assay is being developed as a potential companion diagnostic for AstraZeneca and Daiichi Sankyo's ADC Datroway.

The firm said it will enroll more ovarian cancer patients in its ongoing Phase II trial to gather data for a regulatory submission for rezatapopt to the FDA.

The firm will use the proceeds to fund clinical trials in thyroid eye disease, diabetes, geographic atrophy, and other chronic diseases.

The company will use the funds to advance a CAR T-cell therapy it is developing for treating AL amyloidosis, a bone marrow disease.